| 24.49 |  +0.35 / +1.45%Today’s Change | 23.93 Today|||52-Week Range 50.44 | -15.76% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $1.9B |
Company Description
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through Diagnostics and Other segments. The Diagnostics segment engages in the provision of testing and collaborative development of testing that is designed to asses a risk of developing a disease later in life of an individual. The Other segmeng provides products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake, UT.
Employees
Shareholders
| Other institutional | 55.46% |
| Mutual fund holders | 54.72% |
| Individual stakeholders | 4.60% |
Top Executives
| Mark C. Capone | President, Chief Executive Officer & Director |
| Gary A. King | Executive Vice President-International Operations |
| R. Bryan Riggsbee | CFO, Treasurer, Principal Accounting Officer & EVP |
| Robert Gardner Harrison | Chief Information Officer |
| Jerry S. Lanchbury | Chief Scientific Officer |
+0.35 / +1.45%
